---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Effect on quality measures"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Effect on quality measures. Topics: Merit-based Incentive Payment System 2026 measure 279: assessment of adherence to obstructive sleep apnea therapy; Merit-based Incentive Payment System 2026 measure 277: severity assessment at initial diagnosis; American Academy of Sleep Medicine adult obstructive sleep apnea quality measure set, 2022 update. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Effect on quality measures

<a id="heading-2.1.2.13"></a>

## 2.1.2.13 Effect of AD109 on Quality Measures

<a id="topic-2.1.2.13-1"></a>

### Product-specific effect on quality measures

No evidence found.

<a id="topic-2.1.2.13-2"></a>

### Merit-based Incentive Payment System 2026 measure 279: assessment of adherence to obstructive sleep apnea therapy

> “Percentage of patients aged 18 years and older with a diagnosis of obstructive sleep apnea (OSA) that were prescribed an evidence-based therapy that had documentation that adherence to therapy was assessed at least annually through an objective informatics system or through self-reporting (if objective reporting is not available).”
> “Evidence-based Therapy – includes positive airway pressure, oral appliances, positional therapies, hypoglossal nerve stimulation, or other devices with monitoring capabilities.”
> “Objective Informatics – a telemonitoring system that shows data demonstrating patient adherence to the prescribed therapy for obstructive sleep apnea (i.e., CPAP machines with SD cards that store data).”
> “This recommendation is based on evidence that therapy adherence is extremely important for patients with OSA to experience improvement in signs and symptoms of OSA.”

Source: [CMS Quality Payment Program measure 279 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_279_MIPSCQM.pdf)

<a id="topic-2.1.2.13-3"></a>

### Merit-based Incentive Payment System 2026 measure 277: severity assessment at initial diagnosis

> “Percentage of patients aged 18 years and older with a diagnosis of obstructive sleep apnea who had an apnea hypopnea index (AHI), a respiratory disturbance index (RDI), or a respiratory event index (REI) documented or measured within 2 months after initial evaluation for suspected obstructive sleep apnea.”

Source: [CMS Quality Payment Program measure 277 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_277_MIPSCQM.pdf)

<a id="topic-2.1.2.13-4"></a>

### American Academy of Sleep Medicine adult obstructive sleep apnea quality measure set, 2022 update

> “Two of the measures are currently included in the Merit-based Incentive Payment System (MIPS) program, which replaced the PQRS program, as a part of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).”
> “For the purposes of this measure, evidence-based therapies include positive airway pressure, oral appliances (custom, titratable, Food and Drug Administration [FDA]–cleared appliances), positional therapies, upper airway surgeries, hypoglossal nerve stimulation.”
> “Proportion of patients aged 18 years and older diagnosed with OSA that showed any improvement in their quality of life (QoL) from baseline within 1 year of starting treatment.”
> “The Task Force reviewed this measure and agreed that, although there is not yet convergence on exactly which HRQoL instrument should be used, this is an important outcome to measure and document, as it will speak to the effectiveness of the assessments and treatment captured in the process measures.”
> “The registry is approved by CMS as a Qualified Clinical Data Registry, for reporting quality measures as a part of the Quality Payment Program, a national quality reporting initiative that includes MIPS.”

Source: [Lloyd et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9622990/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
